Search PubMed⌕ Search

Biomedical subjects

K Haeger

Publications and source records attributed to K Haeger.

At least 19 recordsLinked to original sources
PubMed1979

Netilmicin: clinical evaluation of efficacy and toxicity of a new aminoglycoside.

The efficacy and toxicity of netilmicin, a new semisynthetic aminoglycoside, was clinically evaluated in fifty-two patients with moderate to severe infections with Gram-negative rods or Staph. aureus. Average duration of treatment was 14 days and mean total dose 2,960 mg. One-hour mean value of netilmicin serum concentration was 6.4 microgram/ml and mean trough value 1.2 microgram/ml. Forty-four patients were cured or improved. In twenty-one of them the effect could be attributed to netilmicin alone; the other twenty-three had a combined therapy. No improvement took place in five, but four of them could not be regarded as netilmicin failure. One patient with Pseudomonas aeruginosa infection was possible failure. The sensitivity of the causative bacteria to netilmicin was studied and compared with amikacin, gentamicin, sisomicin and tobramycin. Vestibular function and hearing acuity was thoroughly examined by electronystagmography and audiography. Drug-related VIIIth nerve damage could not be confirmed in any of our patients. Five patients showed a rise of serum creatinine of 30 mumol/l. This shows that netilmicin, similar to other aminoglycosides, is a potential nephrotoxic drug. Netilmicin appears to be an efficacious aminoglycoside and the oto- and nephrotoxicity is low, if careful attention is paid to the renal function and the serum concentrations of the drug.

Adolescent↗
PubMed1978

Netilmicin treatment of serious infections in patients with renal insufficiency.

Out of 24 patients with suspected moderate to severe infections and treated with the semisynthetic aminoglycoside netilmicin, 11 patients had decreased renal function. Non-bacterial aetiology was present in five cases. There was good netilmicin effect in 10 cases, indeterminate effect in 6 cases (due to simultaneously given other antibiotics) and failure in 3 cases. Pharmacokinetic parameters were studied. Curves are given for serum concentration patterns relative to creatinine clearance, and serum half-lives are calculated in renal dysfunction. In this series of very ill patients including impaired renal function, metilmicin proved to be an efficient antibiotic with low toxicity. Only one transient minor vestibular abnormality in an 80-year-old man with concomitant diuretic medication was registered.

Aged↗
PubMed1978

Susceptibility of 327 clinical isolates to netilmicin.

Netilmicin, a semisynthetic derivative of sisomicin, was tested against 327 isolates of Staphylococcus aureus, Pseudomonas aeruginosa and Gram-negative enteric bacilli. Seventy-two per cent of the isolates were inhibited at a concentration of 0.5 microgram netilmicin per ml, and 93% of the isolates were susceptible to 4 microgram per ml or less. The MICs of netilmicin and gentamicin for 24 Providencia and 38 Pseudomonas isolates were compared. The activity of netilmicin closely paralleled that of gentamicin, 46% of the Providencia isolates and 32% of the Pseudomonas isolates not being inhibited by 4 microgram per ml of either drug.

Enterobacteriaceae↗
PubMed1977

Efficacy and tolerance of Flunixin (SCH 14714) in the treatment of postoperative pain, with observations on the methodology of postoperative pain studies.

A new anti-inflammatory, antipyretic and analgesic drug 2(2'-methyl-3'-trifluoromethylanilino)-nicotinic acid (Flunixin, Sch 14714) was compared with aspirin and a placebo in a double-blind study of pain after four different types of operation. Sch 14714 proved to be superior to the two other drugs after herniorraphy and venous surgery of the leg. The frequency of adverse effects after this drug was, at most. 1.2% which did not differ from the side-effect rates of aspirin or placebo. The second and third days after operation yielded a very high rate of optimal pain relief scores resulting in poor discrimination. Thus cross-over studies seem to be superfluous in the study of pain-relieving drugs in the period following surgery. The patients' rather low demand of analgesic drugs indicated that more stringent enrollment criteria should be adhered to. It was also shown that radical venous surgery constituted a good model for pain studies.

Aniline Compounds↗
PubMed1977

Sisomicin treatment of serious neonatal infections. A clinical and pharmacokinetic study.

23 infants, 20 of which had verified or clinically highly suspected serious infections in the neonatal period, were treated with a new antibiotic aminoglycoside, sisomicin, i.m. in doses from 2.8 to 6.6 mg/kg/24 h. Clinical cure was obtained in 18 of 20 caes, and marked improvement in one case. Adverse effects were only observed in two infants with tenderness at the injection sites. Serum concentrations and half-life estimations showed that the concentrations were similar to those obtained for gentamicin, and that half-life was independent of postnatal age, but highly correlated to the gestational age and to body weight. Consideration should therefore be given to the prolonged half-life of the drug in immature and low birth weight infants.

Anti-Bacterial Agents↗
PubMed1976

A new principle for the cleansing of infected wounds.

When dry porous hydrophilic beads, formed by a three dimensional network of dextran polymers, are placed on a discharging wound, they absorb the exudate and swell to form of a gelatinous layer. Within this gelatinous layer a separation of substances occurs according to their molecular weights, with the smaller (MW less than 1000) freely penetrating the pores of the beads and the larger (MW greater than 5 000) remaining in the interspaces. Since proteins are removed from the wound surface with the fluid, crustformation on the wound is prevented. Clotting within the gel layer does not occur, since, as shown in another study (Aberg, Hedner, Jacobsson & Rothman 1976), wound exudate contains a high amount of fibrin-fibrinogen split products and no coagulable fibrinogen. Therefore as long as dry beads are available, exudate can be sucked up. With the wound exudate bacteria, degradation products and toxins are removed from the wound surface. A substance with the above described properties Debrisan (Pharmacia AB, Sweden) was used to treat various types of wounds. The treatment was most effective for profusely discharging infected wounds. Within a few days inflammation subsided, exudate decreased and granulation tissue appeared. So far no side effects are observed and even patients, who during years of treatment of leg ulcers had become sensitized to most dressings and local antibiotics could be treated. The new technique for sampling of wound fluid also offers a model for studies on inflammatory mediators and protein loss.

Administration, Topical↗